Immune checkpoint inhibitors（ICPIs）including anti ⁃cytotoxic T lymphocyte antigen 4，anti ⁃ programmed cell death 1 and anti⁃programmed cell death 1 ligand antibodies are novel therapeutic agents targeting a variety of cancers and show good therapeutic effect in clinical practice. However，a wide range of immune⁃related adverse reactions（irAEs）are reported during their application，during which the endocrine organ damage is the most common，and it affects the anti⁃tumor effect and patient′s quality of life.This article reviews the clinical char⁃ acteristics，possible pathogenesis and management strategies of immune⁃related adverse reactions of ICPIs therapy.